Biktarvy

Biktarvy approved for the treatment of HIV-1 infection

Biktarvy approved for the treatment of HIV-1 infection The FDA has approved Biktarvy a once-daily single-tablet regimen for the treatment of HIV-1 infection… Gilead Sciences, Inc. has announced that the US Food and Drug Administration (FDA) has approved Biktarvy (bictegravir 50mg,emtricitabine 200mg/tenofovir alafenamide 25mg; BIC/FTC/TAF), a once-daily single-tablet regimen (STR) for the treatment of HIV-1 infection. […]